These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 22837094

  • 1. Phase IIa study of the immunogenicity and safety of the novel Staphylococcus aureus vaccine V710 in adults with end-stage renal disease receiving hemodialysis.
    Moustafa M, Aronoff GR, Chandran C, Hartzel JS, Smugar SS, Galphin CM, Mailloux LU, Brown E, Dinubile MJ, Kartsonis NA, Guris D.
    Clin Vaccine Immunol; 2012 Sep; 19(9):1509-16. PubMed ID: 22837094
    [Abstract] [Full Text] [Related]

  • 2. The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710): results of two Phase I studies.
    Harro CD, Betts RF, Hartzel JS, Onorato MT, Lipka J, Smugar SS, Kartsonis NA.
    Vaccine; 2012 Feb 21; 30(9):1729-36. PubMed ID: 22192849
    [Abstract] [Full Text] [Related]

  • 3. Safety and immunogenicity of a novel Staphylococcus aureus vaccine: results from the first study of the vaccine dose range in humans.
    Harro C, Betts R, Orenstein W, Kwak EJ, Greenberg HE, Onorato MT, Hartzel J, Lipka J, DiNubile MJ, Kartsonis N.
    Clin Vaccine Immunol; 2010 Dec 21; 17(12):1868-74. PubMed ID: 20943877
    [Abstract] [Full Text] [Related]

  • 4. Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: Phase III randomized study.
    Fattom A, Matalon A, Buerkert J, Taylor K, Damaso S, Boutriau D.
    Hum Vaccin Immunother; 2015 Dec 21; 11(3):632-41. PubMed ID: 25483694
    [Abstract] [Full Text] [Related]

  • 5. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial.
    Fowler VG, Allen KB, Moreira ED, Moustafa M, Isgro F, Boucher HW, Corey GR, Carmeli Y, Betts R, Hartzel JS, Chan IS, McNeely TB, Kartsonis NA, Guris D, Onorato MT, Smugar SS, DiNubile MJ, Sobanjo-ter Meulen A.
    JAMA; 2013 Apr 03; 309(13):1368-78. PubMed ID: 23549582
    [Abstract] [Full Text] [Related]

  • 6. Naturally occurring IgG antibody levels to the Staphylococcus aureus protein IsdB in humans.
    Zorman JK, Esser M, Raedler M, Kreiswirth BN, Ala'Aldeen DA, Kartsonis N, Smugar SS, Anderson AS, McNeely T, Arduino JM.
    Hum Vaccin Immunother; 2013 Sep 03; 9(9):1857-64. PubMed ID: 23778314
    [Abstract] [Full Text] [Related]

  • 7. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis.
    Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, Yeoh H, Law D, Robbins JB, Schneerson R, Muenz L, Fuller S, Johnson J, Fireman B, Alcorn H, Naso R.
    N Engl J Med; 2002 Feb 14; 346(7):491-6. PubMed ID: 11844850
    [Abstract] [Full Text] [Related]

  • 8. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model.
    Kuklin NA, Clark DJ, Secore S, Cook J, Cope LD, McNeely T, Noble L, Brown MJ, Zorman JK, Wang XM, Pancari G, Fan H, Isett K, Burgess B, Bryan J, Brownlow M, George H, Meinz M, Liddell ME, Kelly R, Schultz L, Montgomery D, Onishi J, Losada M, Martin M, Ebert T, Tan CY, Schofield TL, Nagy E, Meineke A, Joyce JG, Kurtz MB, Caulfield MJ, Jansen KU, McClements W, Anderson AS.
    Infect Immun; 2006 Apr 14; 74(4):2215-23. PubMed ID: 16552052
    [Abstract] [Full Text] [Related]

  • 9. Mortality among recipients of the Merck V710 Staphylococcus aureus vaccine after postoperative S. aureus infections: an analysis of possible contributing host factors.
    McNeely TB, Shah NA, Fridman A, Joshi A, Hartzel JS, Keshari RS, Lupu F, DiNubile MJ.
    Hum Vaccin Immunother; 2014 Apr 14; 10(12):3513-6. PubMed ID: 25483690
    [Abstract] [Full Text] [Related]

  • 10. Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in hemodialysis patients.
    Fattom A, Fuller S, Propst M, Winston S, Muenz L, He D, Naso R, Horwith G.
    Vaccine; 2004 Dec 16; 23(5):656-63. PubMed ID: 15542186
    [Abstract] [Full Text] [Related]

  • 11. Safety and immunogenicity of a recombinant Staphylococcus aureus α-toxoid and a recombinant Panton-Valentine leukocidin subunit, in healthy adults.
    Landrum ML, Lalani T, Niknian M, Maguire JD, Hospenthal DR, Fattom A, Taylor K, Fraser J, Wilkins K, Ellis MW, Kessler PD, Fahim RE, Tribble DR.
    Hum Vaccin Immunother; 2017 Apr 03; 13(4):791-801. PubMed ID: 28010246
    [Abstract] [Full Text] [Related]

  • 12. Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial.
    Levy J, Licini L, Haelterman E, Moris P, Lestrate P, Damaso S, Van Belle P, Boutriau D.
    Hum Vaccin Immunother; 2015 Apr 03; 11(3):620-31. PubMed ID: 25715157
    [Abstract] [Full Text] [Related]

  • 13. A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults.
    Nissen M, Marshall H, Richmond P, Shakib S, Jiang Q, Cooper D, Rill D, Baber J, Eiden J, Gruber W, Jansen KU, Emini EA, Anderson AS, Zito ET, Girgenti D.
    Vaccine; 2015 Apr 08; 33(15):1846-54. PubMed ID: 25707693
    [Abstract] [Full Text] [Related]

  • 14. Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study.
    Frenck RW, Creech CB, Sheldon EA, Seiden DJ, Kankam MK, Baber J, Zito E, Hubler R, Eiden J, Severs JM, Sebastian S, Nanra J, Jansen KU, Gruber WC, Anderson AS, Girgenti D.
    Vaccine; 2017 Jan 05; 35(2):375-384. PubMed ID: 27916408
    [Abstract] [Full Text] [Related]

  • 15. Immunodominance of Epitopes and Protective Efficacy of HI Antigen Are Differentially Altered Using Different Adjuvants in a Mouse Model of Staphylococcus aureus Bacteremia.
    Chen Z, Gou Q, Xiong Q, Duan L, Yuan Y, Zhu J, Zou J, Chen L, Jing H, Zhang X, Luo P, Zeng H, Zou Q, Zhao Z, Zhang J.
    Front Immunol; 2021 Jan 05; 12():684823. PubMed ID: 34122448
    [Abstract] [Full Text] [Related]

  • 16. Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial.
    Creech CB, Frenck RW, Sheldon EA, Seiden DJ, Kankam MK, Zito ET, Girgenti D, Severs JM, Immermann FW, McNeil LK, Cooper D, Jansen KU, Gruber W, Eiden J, Anderson AS, Baber J.
    Vaccine; 2017 Jan 05; 35(2):385-394. PubMed ID: 27866765
    [Abstract] [Full Text] [Related]

  • 17. NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults.
    Schmidt CS, White CJ, Ibrahim AS, Filler SG, Fu Y, Yeaman MR, Edwards JE, Hennessey JP.
    Vaccine; 2012 Dec 14; 30(52):7594-600. PubMed ID: 23099329
    [Abstract] [Full Text] [Related]

  • 18. Protection of mice against Staphylococcus aureus infection by a recombinant protein ClfA-IsdB-Hlg as a vaccine candidate.
    Delfani S, Mohabati Mobarez A, Imani Fooladi AA, Amani J, Emaneini M.
    Med Microbiol Immunol; 2016 Feb 14; 205(1):47-55. PubMed ID: 26155981
    [Abstract] [Full Text] [Related]

  • 19. S. aureus colonization in healthy Australian adults receiving an investigational S. aureus 3-antigen vaccine.
    Marshall HS, Baber J, Richmond P, Nissen M, Shakib S, Kreiswirth BN, Zito ET, Severs J, Eiden J, Gruber W, Jansen KU, Jones CH, Anderson AS.
    J Infect; 2019 Dec 14; 79(6):582-592. PubMed ID: 31585191
    [Abstract] [Full Text] [Related]

  • 20. Immunity to Staphylococcus aureus: Implications for Vaccine Development.
    Proctor RA.
    Microbiol Spectr; 2019 Jul 14; 7(4):. PubMed ID: 31298209
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.